Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
13.80
-0.32 (-2.27%)
At close: Feb 27, 2026, 4:00 PM EST
14.00
+0.20 (1.45%)
After-hours: Feb 27, 2026, 7:44 PM EST
Amarin Corporation Revenue
In the year 2025, Amarin Corporation had annual revenue of $213.65M, down -6.55%. Amarin Corporation had revenue of $49.22M in the quarter ending December 31, 2025, a decrease of -21.00%.
Revenue (ttm)
$213.65M
Revenue Growth
-6.55%
P/S Ratio
1.34
Revenue / Employee
$776,895
Employees
275
Market Cap
286.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 213.65M | -14.97M | -6.55% |
| Dec 31, 2024 | 228.61M | -78.30M | -25.51% |
| Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
| Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
| Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 62.58B |
| Sanofi | 54.85B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
| Biogen | 9.89B |
| Grifols | 8.83B |
| Organon & Co. | 6.22B |
| Scilex Holding Company | 40.36M |
AMRN News
- 3 days ago - Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease - GlobeNewsWire
- 6 weeks ago - US Supreme Court to hear 'skinny label' patent fight involving Amarin - Reuters
- 7 weeks ago - Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization - GlobeNewsWire
- 3 months ago - New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients - GlobeNewsWire
- 4 months ago - Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 4 months ago - Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress - GlobeNewsWire